CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 96 enrolled
Drug / intervention
Lithiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06751875
NCT06751875N/ACompleted

Preventing Relapse After Successful Electroconvulsive Therapy for Depression. A Randomized Controlled Trial on Lithium as add-on to Personalized Maintenance ECT.

Universiteit Antwerpen·interventional·Posted Dec 30, 2024·Updated May 5, 2026

In Brief

A clinical study evaluating Lithium for Major Depressive Disorder (MDD). Completed, enrolled 96 participants across 1 site.

Detailed Summary

The present project is designed to study two promising relapse prevention strategies in an RCT. This will be the first project worldwide to study the effects of a personalized ECT treatment algorithm in the continuation phase of depression in an ECT-responsive population of all ages. The project holds promise for diminishing relapse rates after successful ECT, thereby being of potential impact for a vulnerable group of patients with an often-recurring form of major depressive disorder. The underinvestigated role of lithium after successful ECT is the focus of our project. In order to improve implementation options, the investigators assess self-rating of mood alongside clinician-ratings. To investigate the effectiveness of these strategies, a multidisciplinary research project with partners from UAntwerp as well as PZ Duffel, KULeuven, AZ Sint-Jan in Brugge and our Dutch partner UMC Rotterdam was set up. With the expertise, skills and patients available at the consortium participants, the research team will be able to address the challenges of the project in terms of planning and organization of the treatment and testings. This is a completely clinical study with the intent to decrease relapse rates after successful ECT. The concrete scientific objectives (SO) will be the following: * SO1: Investigate the additive effect of lithium-addition to symptom-driven M-ECT and antidepressant treatment in preventing relapse after successful ECT. * SO2: Validate the effectiveness of a personalized, symptom-driven approach of maintenance ECT (for 6 months) in depressive patients that have responded to an acute ECT-course. * SO3: Compare clinician-rated mood with scores on self-rating scales. * SO4: Evaluate the tolerability of combined continuation treatment in the two different treatment arms by assessment of cognitive functioning.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 30, 2024
Enrollment StartJul 26, 2019
Primary CompletionDec 1, 2024
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 1.5 years ago

Interventions

Lithiumdrug

Patients are randomized to either receive lithium or not.